EU announces 246 million Euros of medical research funding and tells us what they are looking for in the next round
The European Commission and the EFPIA announced on Monday that 15 research projects were selected to receive a total of 246 million Euros (US$333 million) in research funding made available through the Innovative Medicines Initiative (IMI). The selected projects will address the main causes of bottlenecks in the pharmaceutical R&D process.
the 15 projects will focus on the health issues such as diabetes, psychiatric disorders, severe asthma and pain. The Pharmaceutical industry provides 136 million Euros (US$184million) through provision of their resources, facilities, materials and staff, and the remaining 110 million Euros goes to other participants such as small businesses, patient groups and academic groups.
The next call for proposals, is in the autumn and they will be seeking products in Oncology, Chronic Inflammatory disease, among others.
If you would like more detail in this area please get in touch with Damien Bové damien.bove@idaconsultants.com
Damien Bové works as a drug development consultant (pharmaceutical or biotechnology) and regulatory consultant, we work with our clients to define a drug development target, define a drug development strategy, define a regulatory strategy or define a commercial strategy. Our clients are generally raising funds or looking to license out their technology and we help them achieve it. If you want to know more don’t hesitate to get in touch.
As you know this website is a great resourse for keeping up to date with developments and regulations, why not get our FREE monthly regulatory and market round up. You can un-subscribe at any time and we do not share your details with anybody.
